Vinati Organicsspecialty chemicalsswing tradingpositional investingETH Research Desk

Vinati Organics Fell 35 Percent on One Flat Year. The Recovery Has Already Started. The Price Has Not.

Profile picture of Prateek Goel
Prateek Goel · INH00002639016 Jul 2026 · 4 min read · Updated 16 Jul 2026, 08:00 am
Vinati Organics Fell 35 Percent on One Flat Year. The Recovery Has Already Started. The Price Has Not.

Here is a riddle the market got wrong this year. A debt-free company, the world's largest maker of its main product, grows profit 17.5 percent to an all time record of Rs 488 crore. The stock falls 35 percent.

That company is Vinati Organics, and the ETH Research Desk has just published a full BUY report on it. This article gives you the short version.

Vinati is the world's largest producer of ATBS, a molecule used in water treatment, oil field chemicals, textiles and personal care, and of IBB, the key raw material for ibuprofen. It runs two plants in Maharashtra, carries zero debt, holds about Rs 190 crore in treasury, and the promoter family owns 74.28 percent with zero shares pledged. Every expansion in its history has been paid for in cash.

So what broke? One flat revenue year. ATBS demand slowed from October 2025 and IBB volumes fell about 20 percent on a raw material problem that has since been resolved. Revenue stayed flat at around Rs 2,280 crore. The market graded the year on the top line and took the stock from Rs 2,040 down to a low of Rs 1,203 in April 2026.

Underneath that flat top line, EBITDA grew 13 percent, the Q4 margin printed 28.2 percent against a guided band of 26 to 27 percent, and standalone profit hit a record. A company that grows profit 17.5 percent in its worst demand year in a decade is telling you what the cost structure does in a normal one.

Now the top line is the thing changing. ATBS demand turned in April 2026. The capacity expansion is already built and paid for, Phase 1 completed in October 2025 and Phase 2 in April 2026. Management has guided 15 to 20 percent volume growth for FY27. The Veeral Organics subsidiary plus two to three new specialty chemicals begin contributing from H2 FY27, with antioxidants and butyl phenols targeted at Rs 800 to 900 crore of combined revenue within two years.

At Rs 1,315 the stock trades near 30 times earnings, its cheapest multiple in years for a franchise that has commanded roughly 40 times through most of a decade. Even at the April panic low it did not break 28 times.

The Desk's plan carries two clocks.

The swing plan targets Rs 1,510, about 15 percent, in one to four months. Entry zone Rs 1,280 to 1,330. This target needs no re-rating and no new information, it sits at the 38.2 percent retracement of the entire decline and in the zone where street estimates already sit. The catalyst is Q1 FY27 results in late July or August, the first quarter with the ATBS recovery fully inside it.

The positional plan targets Rs 1,850, about 41 percent, over twelve to eighteen months. Entry Rs 1,250 to 1,330, staggered over weeks. If FY27 guidance lands and the new engines contribute as guided, FY28 EPS works out around Rs 60 to 62, and at today's own multiple of 30 times, with no re-rating assumed, that is Rs 1,800 to 1,860.

Both plans share one common stop: a weekly close below Rs 1,180. Both carry kill switches written down in advance. If Q1 FY27 shows no volume growth, the swing exits regardless of price. If volume growth stays below 15 percent for two consecutive quarters, or Veeral Organics slips past H2 FY27, the position exits into strength. If any exit condition triggers, we will publish a review note rather than quietly hoping. That is the Open Desk Standard.

The full report carries the Forensic Scorecard, six checks on earnings quality and promoter behaviour before any price talk, the three scenario valuation with bear, base and bull prices, the complete technical structure, and the shareholding read. Find it on the Equity Trading Hub portal on InsightPier.

You rarely get to buy quality cheap and early at the same time. Vinati at 30 times, three months off a washout low, one quarter before the guidance meets the tape, is both.

Prepared by the ETH Research Desk. Prateek Goel is a SEBI-Registered Research Analyst (Reg. No. INH000026390). Registration granted by SEBI and NISM certification do not guarantee performance or assure returns. Investment in securities market is subject to market risks. Read all related documents carefully before investing. The CMP of Rs 1,315 is a drafting-date reference, verify live prices before acting. Price targets are based on assumptions that may not materialise. This is research and market commentary, not personalised investment advice.